J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text HTML] [Full Text PDF] （in Japanese / 1016KB） [PDF: Members Only]

J.Jpn. Surg. Soc.. 124(5): 422-430, 2023

Feature topic

PERIOPERATIVE TREATMENT FOR NON-SMALL CELL LUNG CANCER

1) Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
2) Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Japan

Yu Tanaka1), Yoshitaka Zenke1), Koichi Goto1), Masahiro Tsuboi2)

The perioperative treatment for non-small cell lung cancer (NSCLC) has developed as adjuvant chemotherapy with cytotoxic agents. In recent years, perioperative treatment with molecular-targeted agents and immune checkpoint inhibitors has developed rapidly based on the treatment of advanced NSCLC. Osimertinib as postoperative adjuvant therapy for pathological stage II–III EGFR-mutated NSCLC, atezolizumab for pathological stage II–III PD-L1-positive NSCLC, and nivolumab plus platinum-based chemotherapy for clinical stage IB–III resectable NSCLC have recently been approved. This article summarizes the current evidence and issues in advances in perioperative treatment and introduces a large-scale prospective observational study (LC-SCRUM-Advantage/MRD) that we are currently conducting to develop personalized perioperative target therapy and establish new biomarkers.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.